- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06625203
Neintervenční, mezinárodní, multicentrická klinická výzkumná studie k vybudování největší sbírky multimodálních dat (včetně klinických dat, zobrazovacích dat a dat Omics) v onkologii (MOSAIC)
Multi Omics a prostorový atlas v rakovině
Cancer is amongst the leading causes of disease-related morbidity and mortality. A major challenge in cancer treatment is the development of biology-informed, personalised treatment strategies. Recent advances in artificial intelligence (AI) and next-generation sequencing (NGS) technologies have shed further insights into disease biology and treatment pathways, thus identifying new, precision medicine-based therapeutic opportunities.
The biological mechanisms leading to cancer development and progression arise from complex and plastic networks of dysregulated cellular programs involving many signalling pathways and effector molecules. Cancer cells alter their surrounding environment via cell-cell interactions with non-tumor cells or by secreting cytokines, chemokines and other factors. This reprogramming of the tumour microenvironment (TME) is critical for cancer progression, invasion, and metastasis. Moreover, there are increasing studies that show that both innate and adaptive immune cell types contribute to tumorigenesis and treatment resistance when present within the TME. Understanding the crosstalk between cancer cells and the surrounding TME will inform on mechanisms of sensitivity and resistance to treatment, including immunotherapy (IO) and targeted therapies.
Spatially resolved-Omics is an emerging field that characterises cell types by gene/protein expressions within their spatial context in the tissue organisation. Recent high profile spatial transcriptomics studies have uncovered specific cell identities that define the surrounding TME.
The MOSAIC study, a collaborative initiative across industry and top oncology hospitals, proposes to go way beyond current cancer molecular profiling projects by combining the generation and analysis of multiple data modalities (3 essential mandatory modalities: Clinical Data, Hematoxylin and Eosin (H&E) microscopic image, Spatial transcriptomics; up to 3 high priority data modalities depending on technical feasibility and sample size: bulk Ribonucleic Acid Sequencing (RNAseq), bulk Whole Exome Sequencing (WES), Single-cell transcriptomics; and potentially other optional data modalities and follow-up experiments such as single-cell omics, immunohistochemistry and spatial proteomics or other molecular profiling of proteins and molecules) on a minimum of 2,000 tumour samples across a different cancer indications. This will generate broad molecular and cellular profiling data of the tumour and its microenvironment from cancer patients, integrated with clinical data, at an unprecedented scale and resolution.
This study will enroll patients diagnosed with one of the eligible cancer indications and for which a formalin fixed paraffin embedded (FFPE) tumor sample from already performed biopsy and/or surgical resection is available within their local pathology archive or their affiliate centers archives.
The MOSAIC study expects to have a strong impact for patients in terms of new targeted therapeutic drug discovery, identification of patient subgroups requiring either specific treatment or broader clinical care and identification of novel treatment response and resistance mechanisms.
Přehled studie
Postavení
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní místa
-
-
-
Paris, Francie
- Gustave Roussy
-
-
-
-
-
Berlin, Německo
- Charité - Universitätsmedizin Berlin
-
Erlangen, Německo
- Universiy Hospital Erlangen & FAU Erlangen-Nürnberg
-
-
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Spojené státy, 15238
- University of Pittsburgh
-
-
-
-
-
Lausanne, Švýcarsko
- Centre Hospitalier Universitaire Vaudois
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Patients across different cancer indications, which include, but are not restricted to histologically confirmed solid tumors (all types and subtypes) and diffuse large B cell lymphoma (DLBCL) and for which there is a formalin fixed and paraffin embedded (FFPE) tumor sample from already performed biopsy and/or surgical resection available.
Popis
Inclusion Criteria:
-
That the patient was over the age of 18 when the sample was taken/consented to.
-
Availability of patient informed consent or non-opposition form to perform exploratory research matching at least one of the MOSAIC objectives (unless authorisation is granted by the local Institutional Review Board / Independent Ethics Committee (IRB/IEC) for the use of samples in the study according to local regulations and law).
-
Have a confirmed diagnosis based on international criteria for the relevant tumor type.
-
Confirmed formalin fixed and paraffin embedded (FFPE) tissue availability to generate at least the 3 core data modalities, and preferentially all MOSAIC data modalities.
-
Confirmed availability of associated clinical data.
-
Qualification of the paraffin tissue block meeting all of the following:
- Being of the expected tumor type
- For solid tumors (all cancer indications except diffuse large B cell lymphoma (DLBCL)): Tumor cell content ranging from 40% to 80% on an hematoxylin and eosin (H&E) section within a specified area as dictated by the lab protocol specific to the technique utilized
- For DLBCL, a minimum of 80% of high grade component on an H&E section within a specified area as dictated by the lab protocol specific to the technique utilized
- Wherever possible, the remaining tissue thickness must be over 125 micrometers (indicative range)
- Tumor sample must be <10 years old
In addition, each sub-cohort within each cancer indication will have specific inclusion criteria (e.g., disease stage; sampling site; treatment received…).
Exclusion Criteria:
1. Samples without a preserved tissue architecture, such as cytologies and cytoblocks.
In addition, each sub-cohort within each cancer indication may have specific exclusion criteria (e.g. histological subtype; history of immunosuppression; etc…).
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: COHORT
- Časové perspektivy: RETROSPECTIVE
Kohorty a intervence
Skupina / kohorta |
|---|
|
Pacienti s diagnostikovanou jednou z vhodných rakovin a mající alespoň jeden archivovaný vzorek FFPE
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The primary endpoint will be genes or proteins that present features compatible with drug targeting and/or novel biomarkers, and that are specific to a given patient population within one or more cancer indications.
Časové okno: From date of cancer diagnosis until date of death, date of lost of follow-up, date of consent withdrawal, or date of end of study (Dec 2028), whichever occurs first, assessed up to 16 years
|
Unsupervised data analysis and outcome measures will be used to achieve this, such as prognosis under treatment, response to specific therapies. The response to therapy will be assessed based on the data related to the treatment and its efficacy collected via an electronic Case Report Form. For each patient at baseline and throughout the MOSAIC follow up period, the following data will help to assess this: all the different cancer treatments (surgery,…) and their outcomes ; the concurrent treatment (drug name, …); the state of the cancer, i.e complete or partial response, or progression, measured at various time-points specific to each tumor type. Because the study will utilize tumor samples collected largely <10 years ago, survival information may not be present for all patients by the end of the study, especially in slow evolving tumor types. For this reason, we will use tumor type-specific prognostic markers and scores as surrogates of prognosis whenever available and necessary. |
From date of cancer diagnosis until date of death, date of lost of follow-up, date of consent withdrawal, or date of end of study (Dec 2028), whichever occurs first, assessed up to 16 years
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Biologické mechanismy a/nebo cesty spojené s výsledky léčby pacienta, nezávisle na terapeutickém potenciálu
Časové okno: Od data diagnózy rakoviny do data úmrtí, data ztráty sledování, data odvolání souhlasu nebo data ukončení studie (prosinec 2028), podle toho, co nastane dříve, hodnoceno do 16 let
|
Od data diagnózy rakoviny do data úmrtí, data ztráty sledování, data odvolání souhlasu nebo data ukončení studie (prosinec 2028), podle toho, co nastane dříve, hodnoceno do 16 let
|
|
Nová klasifikace podskupin pacientů v rámci každé indikace rakoviny na základě jedné nebo více datových modalit, které představují homogenní biologii
Časové okno: Od data diagnózy rakoviny do data úmrtí, data ztráty sledování, data odvolání souhlasu nebo data ukončení studie (prosinec 2028), podle toho, co nastane dříve, hodnoceno do 16 let
|
Od data diagnózy rakoviny do data úmrtí, data ztráty sledování, data odvolání souhlasu nebo data ukončení studie (prosinec 2028), podle toho, co nastane dříve, hodnoceno do 16 let
|
|
Nové biomarkery, které mohou být: jeden gen/protein nebo signatura; histologický nebo prostorový rys; kombinovaný biomarker, ideálně přenositelný do rutinního klinického použití, který předpovídá prognózu nebo jiné klinicky použitelné informace.
Časové okno: Od data diagnózy rakoviny do data úmrtí, data ztráty sledování, data odvolání souhlasu nebo data ukončení studie (prosinec 2028), podle toho, co nastane dříve, hodnoceno do 16 let
|
Od data diagnózy rakoviny do data úmrtí, data ztráty sledování, data odvolání souhlasu nebo data ukončení studie (prosinec 2028), podle toho, co nastane dříve, hodnoceno do 16 let
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Studijní židle: M.D., PhD Caroline Hoffmann, Owkin
Publikace a užitečné odkazy
Obecné publikace
- Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012 Mar 20;21(3):309-22. doi: 10.1016/j.ccr.2012.02.022.
- Wu Y, Yang S, Ma J, Chen Z, Song G, Rao D, Cheng Y, Huang S, Liu Y, Jiang S, Liu J, Huang X, Wang X, Qiu S, Xu J, Xi R, Bai F, Zhou J, Fan J, Zhang X, Gao Q. Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level. Cancer Discov. 2022 Jan;12(1):134-153. doi: 10.1158/2159-8290.CD-21-0316. Epub 2021 Aug 20.
- Rao A, Barkley D, Franca GS, Yanai I. Exploring tissue architecture using spatial transcriptomics. Nature. 2021 Aug;596(7871):211-220. doi: 10.1038/s41586-021-03634-9. Epub 2021 Aug 11.
- Meylan M, Petitprez F, Becht E, Bougouin A, Pupier G, Calvez A, Giglioli I, Verkarre V, Lacroix G, Verneau J, Sun CM, Laurent-Puig P, Vano YA, Elaidi R, Mejean A, Sanchez-Salas R, Barret E, Cathelineau X, Oudard S, Reynaud CA, de Reynies A, Sautes-Fridman C, Fridman WH. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity. 2022 Mar 8;55(3):527-541.e5. doi: 10.1016/j.immuni.2022.02.001. Epub 2022 Feb 28.
- Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018 Oct 1;32(19-20):1267-1284. doi: 10.1101/gad.314617.118.
- Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020 Jan 14;52(1):17-35. doi: 10.1016/j.immuni.2019.12.011.
- Cable DM, Murray E, Zou LS, Goeva A, Macosko EZ, Chen F, Irizarry RA. Robust decomposition of cell type mixtures in spatial transcriptomics. Nat Biotechnol. 2022 Apr;40(4):517-526. doi: 10.1038/s41587-021-00830-w. Epub 2021 Feb 18.
- Schmauch B, Herpin L, Olivier A, Duboudin T, Dubois R, Gillet L, Filiot A, Schiratti JB, Di Proietto V, Le Corre D, Bourgoin A, Taieb J, Emile JF, Fridman WH, Pronier E, Laurent-Puig P, Durand EY. A deep learning-based multiscale integration of spatial omics with tumor morphology. Nat Commun. 2025 Nov 27;16(1):11674. doi: 10.1038/s41467-025-66691-y.
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 23.00242.000244
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Pseudonymized, preprocessed, and minimized data belonging to a subset of deceased patients is going to be made available to researchers on the European Genome-Phenome Archive (EGA). This project is called MOSAIC-Window.
In addition, following the ten years of the MOSAIC research study, the collected and generated data within MOSAIC will be anonymized in compliance with applicable laws and regulation, and a public version of the MOSAIC data will be released for research purposes. A dedicated committee of the study will decide on the conditions and modalities of the anonymization.
Časový rámec sdílení IPD
MOSAIC-Window start date: Q3 2024
Kritéria přístupu pro sdílení IPD
Prior to uploading the data to the EGA, Owkin ensures that all personal data embedded in the datasets are pseudonymized and encrypted both in transit and at rest. Owkin is responsible for obtaining and demonstrating the existence of data subjects' informed consent or any other suitable legal basis for processing personal data, obtaining appropriate ethical or other approvals for collecting the data, and complying with applicable Data Protection Laws.
Researchers from institutions outside the MOSAIC Consortium will be able to ask for access to this data, specifying the research questions they want to answer. A Data Access Committee (DAC) will evaluate the researcher's application and decide whether to give access to the MOSAIC-Window dataset or not. If the application is successful, the researcher will agree with the terms and conditions defined by the DAC (e.g. creative common license, no re-identification of patients, etc.) and then will be able to download the data for analysis.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .